AR
KDNY

Advisory Research’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Advisory Research’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,927
Closed -$716K – 509
2023
Q1 		$716K Sell
30,927
-174
-0.6% -$4.15K 0.12% 206
2022
Q4 		$815K Buy
31,101
+2,207
+8% +$48.9K 0.08% 186
2022
Q3 		$568K Buy
+28,894
New +$580K 0.06% 224

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Advisory Research's KDNY Position: Q2 2023 in Review

Advisory Research sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 30,927 shares — an estimated $716K sold.

Advisory Research first reported a position in KDNY in Q3 2022 and held it in 3 quarters. The position peaked at $815K in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • Advisory Research reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Advisory Research sold 30,927 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $716K.
  • Advisory Research first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Advisory Research's Chinook Therapeutics, Inc. Common Stock position peaked at $815K in Q4 2022.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Advisory Research's 13F filing for Q2 2023, filed 14 Aug 2023.